April19

Apri19 is AI-driven drug-discovery company intended to focus on developing and screening novel compounds for psychedelic medicine.

April19

The company uses next-gen machine learning to find novel psychedelic drug compounds aiming to minimize adverse effects and maximize the clinical benefits of the drugs, allowing scientists to unlock the kaleidoscope of untapped possibilities in psychedelic medicine.

“We use next-gen machine learning to find novel psychedelic drug compounds. These compounds aim to minimise adverse effects (e.g. cardiac complications) and maximise clinical benefit (e.g. reduce time to relieve symptoms of depression).”